Home Newsfeeds UBS Maintains Buy on Biogen, Raises Price Target to $309

UBS Maintains Buy on Biogen, Raises Price Target to $309

UBS analyst Colin Bristow maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $238 to $309.

byBenzinga Newsdesk

October 6, 2022

1 minute read

UBS analyst Colin Bristow maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $238 to $309.

F5 Gets Price Target Cuts By Analysts After Q2 Results

By Lisa Levin

April 20, 9:20 AM

F5, Inc. (NASDAQ: FFIV) posted upbeat earnings for its second quarter and announced plans to reduce its global headcount by approximately 620 employees.

FFIV

Stratasys Bags Multi-System Deal From German Manufacturer For H350 3D Printers

By Akanksha Bakshi

March 30, 11:31 AM

Stratasys Ltd. (NASDAQ:SSYS) announces that the German service bureau Götz Maschinenbau has invested in four additional production-scale H350 3D printers. Financial…

NNDM

Benzinga’s Top Ratings Upgrades, Downgrades For October 10, 2023

By Benzinga Insights

October 10, 11:00 AM

Upgrades According to RBC Capital, the prior rating for Montrose Environmental Group Inc (NYSE:MEG) was changed from Sector…

AAP

Cenovus Energy To Invest $4B-$4.5B In 2023

By Bill Haddad

December 6, 7:24 AM

Cenovus Energy Inc. (TSX:CVE) (NYSE:CVE) today announced its 2023 budget, delivering disciplined capital allocation and focused investment plans to progress opportunities across its integrated portfolio, holding oil

CVE

UBS Maintains Buy on Biogen, Raises Price Target to $309

Related Posts

F5 Gets Price Target Cuts By Analysts After Q2 Results

Stratasys Bags Multi-System Deal From German Manufacturer For H350 3D Printers

Benzinga’s Top Ratings Upgrades, Downgrades For October 10, 2023

Cenovus Energy To Invest $4B-$4.5B In 2023